Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03441282 · ClinicalTrials.gov registry record
Precision Medicine in Anesthesia: Genetic Component in Opioid-induced Respiratory Depression
A clinical trial, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- 26
- Enrollment target
NCT03441282: Clinical Trial study, sponsored by University of Alabama at Birmingham.
NCT03441282 is a clinical trial that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03441282 was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- 26 participants
- Enrollment target
Study Summary
The concept of precision medicine - taking individual variability into account when planning preventions and interventions - is not new but is quickly gaining attention in this age of powerful methodology of patient characterization and development of tools to analyze large sets of data. Oncology is the most obvious field in which this information has been readily applied. Increasing focus, nationally and internationally, on developing broad databases of patient genetic information and research efforts evaluating those data will, hopefully, lead to the development and application of evidence-based data enhancing the practice of all fields of medicine. It has yet to become obvious how this information can best be applied to the field of anesthesiology. Most genomics work in anesthesia has been focused in the area of pain medicine. There is a known genetic influence on the potency of opioid-induced analgesia, however; a genetic component of opioid-induced respiratory depression has yet to be thoroughly evaluated. Respiratory depression plays a role in clinical care - from procedures requiring sedation with monitored anesthesia care to treating post-opertative pain and chronic pain - but perhaps its largest current role in the public arena is the unfortunate deaths caused by side effects due to drug overdose. Personalized medicine remains on the horizon for the field of anesthesia, but, as genetic testing becomes more affordable and mainstream in clinical practice, the potential applications are broad. Most readily would be its incorporation into development of patient specific pain regimens. Respiratory depression is a potentially lethal side effect of opioid therapy. In light of the opioid epidemic and CDC-scrutiny of opioid use, determining genetic profiles susceptible to respiratory depression could prove useful in further tailoring the treatment of pain both in the perioperative setting and in the chronic pain management setting.
Primary Outcome
Preop-Blood will be tested for Single Nucleotide Polymorphisms of genes related to opioid-induced analgesia
Interventions
- DRUG Fentanyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-10-30 |
| Est. Completion | 2025-05-21 |
Why NCT03441282 stopped before completion
NCT03441282 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Fentanyl is the first listed.
NCT03441282 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03441282 about?
NCT03441282 is a clinical study titled "Precision Medicine in Anesthesia: Genetic Component in Opioid-induced Respiratory Depression". The concept of precision medicine - taking individual variability into account when planning preventions and interventions - is not new but is quickly gaining attention in this age of powerful methodology of patient characterization and development of tools to analyze large sets of data. Oncology is...
What is the current status of trial NCT03441282?
This trial is currently terminated. The enrollment target is 26 participants. The study started on 2018-10-30. Estimated completion is 2025-05-21.
What interventions are being tested in trial NCT03441282?
The interventions under investigation include: Fentanyl (DRUG).
Who is sponsoring clinical trial NCT03441282?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI